{"@context":{"@vocab":"https://schema.org/"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/fda/warning-letters/check?name=Hubei%20Kangzheng%20Pharmaceutical%20Co.%2C%20Ltd.","name":"Hubei Kangzheng Pharmaceutical Co., Ltd.","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://creativecommons.org/publicdomain/zero/1.0/","primary_source":"https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters","generated_at":"2026-10-08T03:54:23.331Z"},"count":1,"matches":[{"id":"bde946ece77702ad","posted_date":"2022-01-11","letter_issue_date":"2021-11-23","company_name":"Hubei Kangzheng Pharmaceutical Co., Ltd.","issuing_office":"Center for Drug Evaluation and Research | CDER","subject":"CGMP/Finished Pharmaceuticals/Adulterated","canonical_url":"https://api.morvs.ai/fda-warning/bde946ece77702ad"}]}